CAMBRIDGE, Mass.– KOMO Biosciences, a company specializing in next-generation precision genome engineering, has announced the appointment of biotech executive Martin Meeson to its Board of Directors. Meeson, a seasoned leader in the pharmaceutical and biotechnology sectors, brings over two decades of experience that is expected to support KOMO’s ongoing efforts to commercialize its proprietary gene integration technology.
Jennifer Manning, founding CEO and director of KOMO, welcomed the addition, noting that Meeson’s leadership in the contract development and manufacturing space will play a critical role as the company scales its non-viral, non-nuclease genome engineering platform.
“Martin’s deep commercialization and operational expertise will be instrumental as we advance our high-efficiency integrase technology to address urgent needs across industries,” Manning said.
Meeson is currently the CEO of Axplora, a global CDMO specializing in active pharmaceutical ingredients. He previously spent more than 15 years at FUJIFILM Diosynth Biotechnologies, including three years as its president and CEO. His career has been marked by a focus on innovation, strategic growth, and bringing novel therapeutic technologies to market.
“I am deeply impressed by KOMO’s vision and the transformative potential of their technology,” Meeson said. “Their high-efficiency, AI-enabled, site-specific integrase platform represents a major leap forward in delivering large genetic cargo. I’m excited to support their mission and contribute to shaping the future of genome engineering.”
KOMO’s proprietary technology is positioned as a disruptive alternative to current genome editing tools, enabling precise integration without the use of viral vectors or nucleases. The company sees Meeson’s appointment as a strategic step in strengthening its leadership as it continues to expand its commercial footprint and deepen its impact across therapeutic and industrial applications.
His addition to the board underscores KOMO’s broader commitment to assembling a leadership team equipped to guide the company through its next stage of growth in the rapidly evolving field of synthetic biology.
